Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF10.26
-CHF0.03(-0.29%)
At close: 4:00 PM EDT
CHF10.26
-CHF0.03(-0.29%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF13.95
Previous CloseN/A
Volume89.27K
Average Volume (3M)501.06K
Market Cap
CHF672.41M
Enterprise ValueCHF604.15M
Total Cash (Recent Filing)CHF89.80M
Total Debt (Recent Filing)CHF265.68M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 18, 2027EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding54,000,000
10 Day Avg. Volume491,489
30 Day Avg. Volume501,057
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF12.23Price Target Upside19.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.66
Revenue Forecast (FY)CHF1.26B
Bulls Say, Bears Say
Bulls Say
Prescription Growth And RetentionRapid prescription growth and stronger retention in newer electronic-prescription cohorts indicate increasing customer adoption and repeat usage. This can deepen lifetime value, improve revenue visibility, and strengthen DocMorris’s position in the expanding digital pharmacy channel over the next several quarters.
Digital Healthcare ExpansionFast growth in Digital Services and TeleClinic expands DocMorris beyond product fulfillment into recurring healthcare interactions. The stated EBITDA improvement at TeleClinic suggests these platforms can support cross-selling, customer retention, and a more scalable margin profile as utilization increases.
Operating Leverage And Cost SavingsThe combination of improving adjusted EBITDA margins, lower marketing costs, and planned AI-driven savings provides a tangible route toward better operating leverage. If execution continues, recurring efficiencies should support the company’s stated EBITDA breakeven target and reduce its structural cost base.
Bears Say
Persistent Losses And Cash BurnDocMorris remains dependent on a future profitability inflection while operating and free cash flow are materially negative. Continued cash burn can constrain investment, increase reliance on financing, and leave the business less resilient if the planned breakeven milestones are delayed.
Higher Net Debt And Limited FlexibilityRising net debt alongside still-negative operating cash flow reduces financial flexibility during the transition to breakeven. Debt service and funding requirements could absorb resources that would otherwise support growth, while a prolonged delay in cash generation could increase refinancing pressure.
Regulatory And Co-payment PressureChanges to German pharmacy economics and higher patient co-payments could increase price sensitivity and pressure prescription economics. These structural policy effects may limit revenue conversion or margins, particularly if customers respond by reducing purchases or seeking lower-cost alternatives.
DocMorris News
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF13.95 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF672.41M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Mar 18, 2027 which is in 158 days.
How were DocMorris AG’s earnings last quarter?
DocMorris AG released its earnings results on Aug 19, 2026. The company reported -CHF1.1 earnings per share for the quarter.
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate is -0.59.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 54,000,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
DocMorris AG reported an EPS of -CHF1.1 in its last earnings report. Following the earnings report the stock price went up 3.842%.
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF12.23
▲(19.15% Upside)